An artificial intelligence algorithm has outperformed both historical decisions made and the decisions of six expert radiologists.
News
NHS migraine kit to prevent ‘thousands’ of hospital stays
The number of admissions to hospitals in England for headaches and migraines has increased by 14% over the last five years.
Durect abandons DUR-928 after trial hiccup
The drug didn’t show any clinical benefit in any of the trial’s primary or secondary analyses.
NICE refuses Akcea’s Waylivra
The FCS drug was granted a marketing authorisation in May 2019 by the European Commission.
Vaccitech, CR UK link up to develop NSCLC drug
Cancer Research UK will sponsor and manage a Phase I/IIa clinical trial of the drug in combination with current standard of care and first-line treatment
NHS diabetes drive sees public lose ‘weight of 43 ambulances’
89,604 people have now finished the programme, marking the service as a world first of its kind to have achieved a full national roll-out.
Late-stage success for experimental migraine drug
The results support the filing of a New Drug Application (NDA) for Axsome’s AXS-07 in the acute treatment of migraine.
‘Half’ the current chemo could prevent testicular cancer returning
Testicular cancer is the most common cancer affecting young men, with many patients being diagnosed in their twenties or thirties.
Tecentriq hit with draft NICE rejection
The UK watchdog says that the “long-term benefit on overall survival is uncertain”.
BioMarin’s haemophilia gene therapy moves forward in the EU
The submission is the first to be filed in Europe for a gene therapy product for any type of hemophilia
Allergan’s Ubrelvy bags US approval for migraine
The drug is the first oral CGRP receptor antagonist approved to treat acute migraines
Eisai wins clearance for sleep drug Dayvigo
The drug has been approved for insomnia characterised by difficulties with sleep onset and/or sleep maintenance
PRIME status for Abeona’s gene therapy
The novel gene therapy is being developed for the lysosomal storage disease Sanfilippo syndrome type A (MPS IIIA)
Roche buys rights to Sarepta’s DMD gene therapy
Sarepta will receive $1.15 billion upfront and an equity investment
NHS fast-tracks access to Epidyolex for severe epilepsy
Doctors will be able to prescribe the drug from January 6
